Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

CX-801

Fusion protein · Immune activation, directed at interferon alpha/beta receptor · developed by CytomX Therapeutics

Phase 1 Most advanced trial
CTMX Developer
1 Registered trials

What is CX-801?

CX-801 is a masked prodrug of interferon alpha-2b, with peptide masks linked by protease-cleavable linkers. The mask is cleaved by tumor-associated proteases in the tumor microenvironment, releasing active interferon alpha-2b that binds cell-surface interferon receptors and induces interferon-stimulated gene expression with immunomodulatory and antiproliferative effects. It is studied in adult solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Fusion protein
Targets
interferon alpha/beta receptor
Mechanism
Immune activation, directed at interferon alpha/beta receptor
Pathways
interferon signal transduction, ISRE-driven gene transcription
Therapy area
Oncology
Developer
CytomX Therapeutics (CTMX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06462794 Phase 1 Solid Tumor, Adult Recruiting CTMX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Solid Tumor, Adult

More from CytomX Therapeutics

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CTMX page.

Follow CTMX, the company behind CX-801

See CTMX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CTMX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.